Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C14H21NO7S |
Molecular Weight | 347.384 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC(=O)N1[C@@H](C(=O)OCOC(=O)C(C)(C)C)C(C)(C)S2(=O)=O
InChI
InChIKey=OHPVYKXTRACOSQ-ZJUUUORDSA-N
InChI=1S/C14H21NO7S/c1-13(2,3)12(18)22-7-21-11(17)10-14(4,5)23(19,20)9-6-8(16)15(9)10/h9-10H,6-7H2,1-5H3/t9-,10+/m1/s1
Molecular Formula | C14H21NO7S |
Molecular Weight | 347.384 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://en.wikipedia.org/wiki/Sulbactam
http://www.drugbank.ca/drugs/DB09324
Curator's Comment: description was created based on several sources, including
https://en.wikipedia.org/wiki/Sulbactam
http://www.drugbank.ca/drugs/DB09324
Sulbactam is a β-lactamase inhibitor given in combination with β-lactam antibiotics to inhibit β-lactamase, an enzyme produced by bacteria that destroys the antibiotics. Sulbactam in combination with semisynthetic antibiotic ampicillin sodium is indicated for the treatment of infections due to susceptible strains of the designated microorganisms: Skin and Skin Structure Infections caused by beta-lactamase producing strains of Staphylococcus aureus, Escherichia coli etc; Intra-Abdominal Infections caused by beta-lactamase producing strains of Escherichia coli, Klebsiella spp. (including K. Pneumoniae) tec; Gynecological Infections caused by beta-lactamase producing strains of Escherichia coli, and Bacteroides spp. (including B. fragilis).
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P62593 Gene ID: 10076131|||10076142|||13876868|||13877052|||13903673|||13905334|||13905363|||13906404|||13906709|||13906924|||13909533|||13909568|||14612524|||17824300|||17824435|||18157686|||20466965|||20466993|||20467118|||20468340|||20471961|||20491414|||20491639|||20492529|||20492626|||20493584|||2716540|||3244915|||3722457|||4924718|||5961992|||6276043|||8319064|||8319163|||9537966|||9538101|||9846067 Gene Symbol: bla|||blaT-3|||blaT-4|||blaT-5|||blaT-6 Target Organism: Escherichia coli |
0.062 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | UNASYN Approved UseSulbactam Launch Date1988 |
|||
Curative | UNASYN Approved UseSulbactam Launch Date1988 |
|||
Curative | UNASYN Approved UseSulbactam Launch Date1988 |
|||
Curative | UNASYN Approved UseUNASYN is an injectable antibacterial combination consisting of the semisynthetic antibiotic ampicillin sodium and the beta-lactamase inhibitor sulbactam sodium for intravenous and intramuscular administration Launch Date1988 |
|||
Curative | UNASYN Approved UseSulbactam Launch Date1988 |
|||
Curative | UNASYN Approved UseSulbactam Launch Date1988 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
15.36 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2338029 |
0.5 g single, intramuscular dose: 0.5 g route of administration: Intramuscular experiment type: SINGLE co-administered: AMPICILLIN |
SULBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
40.33 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2338029 |
0.5 g single, intramuscular dose: 0.5 g route of administration: Intramuscular experiment type: SINGLE co-administered: AMPICILLIN |
SULBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
40.71 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2338029 |
0.5 g 1 times / day steady-state, intravenous dose: 0.5 g route of administration: Intravenous experiment type: STEADY-STATE co-administered: AMPICILLIN |
SULBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
83.79 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2338029 |
1 g 1 times / day steady-state, intravenous dose: 1 g route of administration: Intravenous experiment type: STEADY-STATE co-administered: AMPICILLIN |
SULBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.26 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2338029 |
0.5 g single, intramuscular dose: 0.5 g route of administration: Intramuscular experiment type: SINGLE co-administered: AMPICILLIN |
SULBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.15 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2338029 |
0.5 g 1 times / day steady-state, intravenous dose: 0.5 g route of administration: Intravenous experiment type: STEADY-STATE co-administered: AMPICILLIN |
SULBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.14 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2338029 |
1 g 1 times / day steady-state, intravenous dose: 1 g route of administration: Intravenous experiment type: STEADY-STATE co-administered: AMPICILLIN |
SULBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1 h |
SULBACTAM serum | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
62% |
SULBACTAM serum | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
4 g 3 times / day multiple, intravenous Highest studied dose Dose: 4 g, 3 times / day Route: intravenous Route: multiple Dose: 4 g, 3 times / day Co-administed with:: ampicillin, i.v(8 g, t.i.d) Sources: Page: p.5meropenem, i.v(2g, t.i.d) polymyxin B, i.v(1.43 mg/kg, b.i.d) |
unhealthy n = 13 Health Status: unhealthy Condition: Ventilator-associated pneumonia, caused by colistin-resistant A. baumannii infection Population Size: 13 Sources: Page: p.5 |
|
2 g 2 times / day multiple, intravenous Recommended Dose: 2 g, 2 times / day Route: intravenous Route: multiple Dose: 2 g, 2 times / day Co-administed with:: cefoperazone, i.v Sources: |
unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
An unusual form of Actinomycosis of the mandible with a resultant gross sequester in a 4-year-old child: a case report. | 2001 Spring |
|
Eradication of multi-drug resistant Acinetobacter from an intensive care unit. | 2001 Winter |
|
Nontraditional dosing of ampicillin-sulbactam for multidrug-resistant Acinetobacter baumannii meningitis. | 2002 Apr |
|
Bacteriology and antimicrobial susceptibility of gram-positive cocci isolated from pus specimens of orofacial odontogenic infections. | 2002 Apr |
|
[Acinetobacter, a nosocomial pathogen. Contribution of experimental models]. | 2002 Apr 13 |
|
Surgical antibiotic prophylaxis in a Turkish university hospital. | 2002 Aug |
|
Antimicrobial susceptibility of coagulase-negative staphylococci isolated from bovine mastitis in Argentina. | 2002 Aug |
|
Pharmacokinetics of an ampicillin/sulbactam (2:1) combination in rabbits. | 2002 Aug |
|
Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. | 2002 Aug |
|
Molecular dynamics at the root of expansion of function in the M69L inhibitor-resistant TEM beta-lactamase from Escherichia coli. | 2002 Aug 14 |
|
Efficacy of amoxicillin-sulbactam, given twice-a-day, for the treatment of community-acquired pneumonia: a clinical trial based on a pharmacodynamic model. | 2002 Dec |
|
Application of micellar electrokinetic chromatography to the determination of sultamicillin in oral pharmaceutical preparations. | 2002 Dec 6 |
|
The impact of carbapenemases on antimicrobial development and therapy. | 2002 Feb |
|
[Analysis of prophylactic antibiotics for cesarean section]. | 2002 Jan |
|
[The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion]. | 2002 Jul-Aug |
|
[A case of bronchopulmonary actinomycosis diagnosed by transbronchial biopsy of a bronchial polypoid tumor]. | 2002 Jun |
|
[Microbiological and clinical studies of Haemophilus influenzae isolated at Kitakyushu Municipal Medical Center from 1996 through 1999]. | 2002 Jun |
|
Prevalence of and resistance to anti-microbial drugs in selected microbial species isolated from bulk milk samples. | 2002 Jun |
|
Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients. | 2002 Jun |
|
Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia. | 2002 Jun 1 |
|
CE versus LC for simultaneous determination of amoxicillin/clavulanic acid and ampicillin/sulbactam in pharmaceutical formulations for injections. | 2002 Jun 20 |
|
Low dose sultamicillin in acute sinusitis. | 2002 Mar |
|
The emergence of beta-lactamase resistance in respiratory pathogens. | 2002 Mar |
|
Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem. | 2002 Mar |
|
[Nocardia farcinica: life-threatening chorioiditis under systemic immunosuppression]. | 2002 Mar |
|
Bacteriology and antimicrobial susceptibility in biliary tract disease: an audit of 10-year's experience. | 2002 May |
|
Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: risk factors for colonization and impact of antimicrobial formulary interventions on colonization prevalence. | 2002 May |
|
Substitution of Met-69 by Ala or Gly in TEM-1 beta-lactamase confer an increased susceptibility to clavulanic acid and other inhibitors. | 2002 May 21 |
|
In vitro investigation of the susceptibility of Acinetobacter baumannii strains isolated from clinical specimens to ampicillin/sulbactam alone and in combination with amikacin. | 2002 Nov |
|
First occurrence of transferable extended-spectrum beta-lactamase hydrolyzing cefoperazone in multiresistant nosocomial strains of Klebsiella pneumoniae from two hospitals in Czech and Slovak Republics. | 2002 Oct |
|
Reports of osteopenia/rickets of prematurity are on the increase because of improved survival rates of low birthweight infants. | 2002 Oct |
|
[The efficacy of prophylactic administration of SBT/ABPC for postoperative infection in neurosurgical operations]. | 2002 Oct |
|
Antimicrobial susceptibility of major pathogens of orofacial odontogenic infections to 11 beta-lactam antibiotics. | 2002 Oct |
|
Development of an assay for beta-lactam hydrolysis using the pH-dependence of enhanced green fluorescent protein. | 2002 Oct 15 |
|
[Activity of 14 antimicrobials against Eikenella corrodens]. | 2002 Oct-Dec |
|
The effect of high single dose parenteral vitamin A in addition to antibiotic therapy on healing of maxillary sinusitis in experimental acute sinusitis. | 2002 Sep 24 |
|
Biochemical characterization of a novel extended-spectrum beta-lactamase from Pseudomonas aeruginosa 802. | 2002 Spring |
|
[The impact of antibiotic use on hospital-acquired pneumonia: data of etiology tests]. | 2003 |
|
Catalytic properties of an endogenous beta-lactamase responsible for the resistance of Azospirillum lipoferum to beta-lactam antibiotics. | 2003 Feb |
|
HPLC for in-process control in the production of sultamicillin. | 2003 Feb 26 |
|
Current status of drug resistance among gram-negative bacilli isolated from admitted cases in a tertiary care centre. | 2003 Jan |
|
Acute otitis media and facial nerve paralysis in adults. | 2003 Jan |
|
Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. | 2003 Jan |
|
Spirocyclopropyl beta-lactams as mechanism-based inhibitors of serine beta-lactamases. Synthesis by rhodium-catalyzed cyclopropanation of 6-diazopenicillanate sulfone. | 2003 Jun 19 |
|
Group 1 beta-lactamases of Aeromonas caviae and their resistance to beta-lactam antibiotics. | 2003 Mar |
|
[beta-Lactamase-inhibitor combinations]. | 2003 Mar |
|
Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment. | 2003 May |
|
In vitro activity of penicillin G/sulbactam compared with penicillin and other antibiotics against common organisms causing ear, nose and throat (ENT) infections. | 2003 May |
|
Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. | 2003 May 15 |
|
Spectrum and antibiotic sensitivity of bacteria contaminating the upper gut in patients with malabsorption syndrome from the tropics. | 2003 May 24 |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: UNASYN should be administered by slow intravenous injection over at least 10–15 minutes or can also be delivered in greater dilutions with 50–100 mL of a compatible diluent as an intravenous infusion over 15–30 minutes.
The recommended adult dosage of UNASYN is 1.5 g (1 g ampicillin as the sodium salt plus 0.5 g sulbactam as the sodium salt) to 3 g (2 g ampicillin as the sodium salt plus 1 g sulbactam as the sodium salt) every six hours
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:25:25 GMT 2023
by
admin
on
Fri Dec 15 15:25:25 GMT 2023
|
Record UNII |
2X0WTA96KX
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C260
Created by
admin on Fri Dec 15 15:25:25 GMT 2023 , Edited by admin on Fri Dec 15 15:25:25 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID4048692
Created by
admin on Fri Dec 15 15:25:25 GMT 2023 , Edited by admin on Fri Dec 15 15:25:25 GMT 2023
|
PRIMARY | |||
|
166010
Created by
admin on Fri Dec 15 15:25:25 GMT 2023 , Edited by admin on Fri Dec 15 15:25:25 GMT 2023
|
PRIMARY | RxNorm | ||
|
2493
Created by
admin on Fri Dec 15 15:25:25 GMT 2023 , Edited by admin on Fri Dec 15 15:25:25 GMT 2023
|
PRIMARY | |||
|
9997821
Created by
admin on Fri Dec 15 15:25:25 GMT 2023 , Edited by admin on Fri Dec 15 15:25:25 GMT 2023
|
PRIMARY | |||
|
100000128679
Created by
admin on Fri Dec 15 15:25:25 GMT 2023 , Edited by admin on Fri Dec 15 15:25:25 GMT 2023
|
PRIMARY | |||
|
69388-79-0
Created by
admin on Fri Dec 15 15:25:25 GMT 2023 , Edited by admin on Fri Dec 15 15:25:25 GMT 2023
|
PRIMARY | |||
|
C96733
Created by
admin on Fri Dec 15 15:25:25 GMT 2023 , Edited by admin on Fri Dec 15 15:25:25 GMT 2023
|
PRIMARY | |||
|
CHEMBL423875
Created by
admin on Fri Dec 15 15:25:25 GMT 2023 , Edited by admin on Fri Dec 15 15:25:25 GMT 2023
|
PRIMARY | |||
|
SUB36039
Created by
admin on Fri Dec 15 15:25:25 GMT 2023 , Edited by admin on Fri Dec 15 15:25:25 GMT 2023
|
PRIMARY | |||
|
2X0WTA96KX
Created by
admin on Fri Dec 15 15:25:25 GMT 2023 , Edited by admin on Fri Dec 15 15:25:25 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |